1. Home
  2. MIDD vs BLCO Comparison

MIDD vs BLCO Comparison

Compare MIDD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Middleby Corporation (The)

MIDD

Middleby Corporation (The)

N/A

Current Price

$102.69

Market Cap

6.1B

Sector

Industrials

ML Signal

N/A

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

N/A

Current Price

$16.94

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MIDD
BLCO
Founded
1888
1853
Country
United States
Canada
Employees
N/A
13000
Industry
Industrial Machinery/Components
Ophthalmic Goods
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.1B
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
MIDD
BLCO
Price
$102.69
$16.94
Analyst Decision
Buy
Buy
Analyst Count
11
14
Target Price
★ $155.89
$19.04
AVG Volume (30 Days)
★ 483.9K
288.1K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.10
N/A
Revenue
$3,201,202,000.00
★ $5,101,000,000.00
Revenue This Year
N/A
$7.71
Revenue Next Year
$4.01
$5.86
P/E Ratio
$1,054.10
★ N/A
Revenue Growth
N/A
★ 6.47
52 Week Low
$104.24
$13.77
52 Week High
$180.13
$18.92

Technical Indicators

Market Signals
Indicator
MIDD
BLCO
Relative Strength Index (RSI) 29.20 49.12
Support Level N/A $16.94
Resistance Level $113.85 $17.21
Average True Range (ATR) 2.57 0.39
MACD -0.12 -0.03
Stochastic Oscillator 2.89 45.28

Price Performance

Historical Comparison
MIDD
BLCO

About MIDD Middleby Corporation (The)

The Middleby Corp is engaged in the foodservice industry. The company develops and manufactures a broad line of solutions used in commercial foodservice and food processing. The group showcases its solutions in the Middleby Innovation Kitchens for commercial foodservice and industrial baking and protein Innovation Centers for food processing solutions.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: